Cargando…
Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective and safe lipid-lowering treatments (LLT). The primary endpoint of the study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410302/ https://www.ncbi.nlm.nih.gov/pubmed/36012937 http://dx.doi.org/10.3390/jcm11164701 |
_version_ | 1784775060584660992 |
---|---|
author | Fogacci, Federica Giovannini, Marina Grandi, Elisa Imbalzano, Egidio Degli Esposti, Daniela Borghi, Claudio Cicero, Arrigo F. G. |
author_facet | Fogacci, Federica Giovannini, Marina Grandi, Elisa Imbalzano, Egidio Degli Esposti, Daniela Borghi, Claudio Cicero, Arrigo F. G. |
author_sort | Fogacci, Federica |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective and safe lipid-lowering treatments (LLT). The primary endpoint of the study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after the recent enlargement of reimbursement criteria. For this study, we consecutively considered the clinical record forms of 6231 outpatients consecutively admitted at the Lipid Clinic of the University Hospital of Bologna (Italy). Patients were stratified according to whether they were allowed or not allowed to access to treatment with PCSK9 inhibitors based on national prescription criteria and reimbursement rules issued by the Italian Medicines Agency (AIFA). According to the indications of the European Medicines Agency (EMA), 986 patients were candidates to treatment with PCSK9 inhibitors. However, following the prescription criteria issued by AIFA, only 180 patients were allowed to access to PCSK9 inhibitors before reimbursement criteria enlargement while 322 (+14.4%) with the current ones. Based on our observations, low-cost tailored therapeutic interventions for individual patients can significantly reduce the number of patients potentially needing treatment with PCSK9 inhibitors among those who are not allowed to access to the treatment. The application of enlarged reimbursement criteria for PCSK9 inhibitors could mildly improve possibility to adequately manage high-risk hypercholesterolemic subjects in the setting of an outpatient lipid clinic. |
format | Online Article Text |
id | pubmed-9410302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94103022022-08-26 Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients Fogacci, Federica Giovannini, Marina Grandi, Elisa Imbalzano, Egidio Degli Esposti, Daniela Borghi, Claudio Cicero, Arrigo F. G. J Clin Med Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective and safe lipid-lowering treatments (LLT). The primary endpoint of the study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after the recent enlargement of reimbursement criteria. For this study, we consecutively considered the clinical record forms of 6231 outpatients consecutively admitted at the Lipid Clinic of the University Hospital of Bologna (Italy). Patients were stratified according to whether they were allowed or not allowed to access to treatment with PCSK9 inhibitors based on national prescription criteria and reimbursement rules issued by the Italian Medicines Agency (AIFA). According to the indications of the European Medicines Agency (EMA), 986 patients were candidates to treatment with PCSK9 inhibitors. However, following the prescription criteria issued by AIFA, only 180 patients were allowed to access to PCSK9 inhibitors before reimbursement criteria enlargement while 322 (+14.4%) with the current ones. Based on our observations, low-cost tailored therapeutic interventions for individual patients can significantly reduce the number of patients potentially needing treatment with PCSK9 inhibitors among those who are not allowed to access to the treatment. The application of enlarged reimbursement criteria for PCSK9 inhibitors could mildly improve possibility to adequately manage high-risk hypercholesterolemic subjects in the setting of an outpatient lipid clinic. MDPI 2022-08-11 /pmc/articles/PMC9410302/ /pubmed/36012937 http://dx.doi.org/10.3390/jcm11164701 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fogacci, Federica Giovannini, Marina Grandi, Elisa Imbalzano, Egidio Degli Esposti, Daniela Borghi, Claudio Cicero, Arrigo F. G. Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients |
title | Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients |
title_full | Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients |
title_fullStr | Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients |
title_full_unstemmed | Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients |
title_short | Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients |
title_sort | management of high-risk hypercholesterolemic patients and pcsk9 inhibitors reimbursement policies: data from a cohort of italian hypercholesterolemic outpatients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410302/ https://www.ncbi.nlm.nih.gov/pubmed/36012937 http://dx.doi.org/10.3390/jcm11164701 |
work_keys_str_mv | AT fogaccifederica managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients AT giovanninimarina managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients AT grandielisa managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients AT imbalzanoegidio managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients AT degliespostidaniela managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients AT borghiclaudio managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients AT ciceroarrigofg managementofhighriskhypercholesterolemicpatientsandpcsk9inhibitorsreimbursementpoliciesdatafromacohortofitalianhypercholesterolemicoutpatients |